| Literature DB >> 34870205 |
Marius Matusevicius1,2, Charith Cooray1,3, Staffan Holmin1,4, Matteo Bottai5, Niaz Ahmed1,6.
Abstract
BACKGROUND: Systolic blood pressure (SBP) after endovascular thrombectomy (EVT) for large artery occlusive stroke is dynamic, requiring adaptable early prediction tools for improving outcomes. We investigated if post-EVT SBP course was associated with outcomes.Entities:
Keywords: cerebrovascular; clinical neurology; stroke
Year: 2021 PMID: 34870205 PMCID: PMC8603273 DOI: 10.1136/bmjno-2021-000183
Source DB: PubMed Journal: BMJ Neurol Open ISSN: 2632-6140
Figure 1Study flowchart. BP, blood pressure; EVT, endovascular thrombectomy; ICH, intracerebral haemorrhage; mRS, Modified Rankin Scale; SICH, symptomatic intracerebral haemorrhage.
Baseline and demographic characteristics and radiological follow-up results
| mRS score 0–2 | mRS score 3–6 | P value | Missing mRS score at 3 months | |
| n | 169 | 175 | 30 | |
| Age* | 66.5 (12.7) | 75.8 (12.1) | <0.001 | 68.6 (10.6) |
| SBP, baseline* | 146.1 (20.8) | 150.2 (27.3) | 0.139 | 148.1 (30.9) |
| Diastolic blood pressure, baseline* | 82.8 (14.3) | 83.5 (18.5) | 0.751 | 86.9 (20.8) |
| Glucose, baseline (mmol/L)* | 7.6 (5.0) | 8.4 (5.1) | 0.140 | 7.6 (2.6) |
| Cholesterol, baseline (mmol/L)* | 4.2 (1.0) | 3.9 (1.1) | 0.026 | 4.0 (1.1) |
| Onset to recanalisation time (min)* | 337.6 (239.4) | 319.5 (207.1) | 0.295 | 337.2 (180.5) |
| EVT procedural time (min)* | 110.9 (98.8) | 129.7 (77.4) | 0.084 | 108.0 (56.7) |
| NIHSS score, baseline† | 13 (7–19) | 18 (13–21) | <0.001 | 14.5 (7.75–19.25) |
| mRS score, baseline† | 0 (0–0) | 0 (0–2) | <0.001 | 0 (0–0) |
| Sex, male‡ | 60.9 (103/169) | 46.9 (82/175) | 0.012 | 46.7 (14/30) |
| Platelet inhibitors, baseline‡ | 16.0 (27/169) | 20.6 (36/175) | 0.336 | 23.3 (7/30) |
| Anticoagulants, baseline‡ | 18.3 (31/169) | 28.0 (49/175) | 0.046 | 6.7 (2/30) |
| Antihypertensive, baseline‡ | 55.0 (93/169) | 66.3 (116/175) | 0.043 | 46.7 (14/30) |
| Statin, baseline‡ | 29.6 (50/169) | 32.0 (56/175) | 0.713 | 20.0 (6/30) |
| Hypertension, baseline‡ | 38.5 (65/169) | 49.1 (86/175) | 0.059 | 40.0 (12/30) |
| Hyperlipidaemia, baseline‡ | 6.5 (11/169) | 6.3 (11/175) | 1.000 | 10 (3/30) |
| Diabetes mellitus, baseline‡ | 8.9 (15/169) | 18.3 (32/175) | 0.017 | 16.7 (5/30) |
| Smoking, baseline‡ | 24.9 (42/169) | 21.7 (38/175) | 0.575 | 16.7 (5/30) |
| Atrial fibrillation, baseline‡ | 26.6 (45/169) | 33.7 (59/175) | 0.189 | 13.3 (4/30) |
| Congestive heart failure‡ | 9.5 (16/169) | 14.9 (26/175) | 0.173 | 3.3 (1/30) |
| Previous TIA‡ | 4.7 (8/169) | 5.7 (10/175) | 0.868 | 3.3 (1/30) |
| Previous stroke‡ | 10.1 (17/169) | 17.7 (31/175) | 0.058 | 13.3 (4/30) |
| Aetiology, CE‡ | 46.2 (78/169) | 54.3 (95/175) | 0.161 | 36.7 (11/30) |
| Aetiology, LAA‡ | 24.3 (41/169) | 26.3 (46/175) | 0.758 | 30.0 (9/30) |
| Aetiology, other‡ | 5.9 (10/169) | 3.4 (6/175) | 0.401 | 0.0 (0/30) |
| Circulation anterior/posterior, anterior‡ | 90.5 (153/169) | 88.6 (155/175) | 0.676 | 93.3 (28/30) |
| ICA‡ | 7.7 (13/169) | 10.9 (19/175) | 0.410 | 3.3 (1/30) |
| T‡ | 10.1 (17/169) | 15.4 (27/175) | 0.184 | 6.7 (2/30) |
| M1‡ | 50.9 (86/169) | 50.9 (89/175) | 1.000 | 66.7 (20/30) |
| M2‡ | 18.3 (31/169) | 10.3 (18/175) | 0.047 | 16.7 (5/30) |
| Basilaris‡ | 6.5 (11/169) | 6.9 (12/175) | 1.000 | 6.7 (2/30) |
| ASPECTS† | 9 (7, 10) | 8 (7, 9) | 0.042 | 8 (7.75, 9) |
| mCTA† | 3 (3, 4) | 3 (2, 4) | 0.394 | 3 (3, 4) |
| IVT treatment‡ | 53.3 (90/169) | 38.9 (68/175) | 0.010 | 50.0 (15/30) |
| mTICI 2b-3 | 86.6 (142/164) | 69.5 (121/174) | <0.001 | 26.7 (8/30) |
| Antihypertensive treatment during 24 hours post-EVT, intravenous‡ | 17.3 (29/169) | 37.1 (65/175) | <0.001 | 16.7 (5/30) |
| Antihypertensive treatment during 24 hours post-EVT, oral‡ | 34.3 (58/169) | 20.6 (36/175) | 0.006 | 23.3 (23/30) |
| Haemorrhagic infarction type I at follow-up of 18–36 hours‡ | 7.7 (13/168) | 10.5 (18/172) | 0.493 | 10.0 (3/30) |
| Haemorrhagic infarction type II at follow-up of 18–36 hours‡ | 0.0 (0/168) | 2.3 (4/172) | 0.137 | 0.0 (0/30) |
| Parenchymal haemorrhage type I at follow-up of 18–36 hours‡ | 3.0 (5/168) | 3.5 (6/172) | 1.000 | 6.7 (2/30) |
| Parenchymal haemorrhage type II at follow-up of 18–36 hours‡ | 2.4 (4/168) | 6.4 (11/172) | 0.124 | 0.0 (0/30) |
| Remote parenchymal haemorrhage type I follow-up of 18–36 hours‡ | 1.2 (2/168) | 0.6 (1/172) | 0.984 | 0.0 (0/30) |
| Remote parenchymal haemorrhage type II at follow-up of 18–36 hours‡ | 0.0 (0/168) | 0.0 (0/172) | – | 0.0 (0/30) |
| Subarachnoid haemorrhage at follow-up of 18–36 hours‡ | 4.2 (7/168) | 9.3 (16/172) | 0.095 | 6.7 (2/30) |
P value calculated for mRS score of 0–2 vs mRS score of 3–6. For group comparisons of continuous and categorical variables, Student’s t-test and Pearson’s χ2 test were used, respectively.
*Mean (SD).
†Median (IQR).
‡Per cent (n cases, n total).
ASPECTS, Alberta Stroke Program Early CT Score; CE, cardiac embolism; EVT, endovascular thrombectomy; ICA, interncal carotid artery; IVT, intravenous thrombolysis; LAA, large artery occlusion; M, middle cerebral artery; mCTA, multiphase CT angiography; mRS, Modified Rankin Scale; mTICI, Modified Treatment in Cerebral Infarction; NIHSS, National Institute of Health Stroke Scale; SBP, systolic blood pressure; T, T-occlusion; TIA, transient ischaemic attack.
Figure 2SBP measurements during the first 24 hours after EVT treatment, by 3-month MRS outcome. EVT, endovascular thrombectomy; mRS, Modified Rankin Scale; SBP, systolic blood pressure.
Fixed effects for the mixed effects models by prediction model version
| Outcome | Models | Level | Trend | Curvature | Twist |
| mRS score 0–2 at 3 months | Linear model | 129.78 | −0.28378 | – | – |
| Quadratic model | 132.50 | −1.2406 | 0.04379 | – | |
| Cubic model | 133.54 | −1.9443 | 0.12573 | −0.00240 | |
| Alive at 3 months | Linear model | 131.02 | −0.23423 | – | – |
| Quadratic model | 133.34 | −1.0488 | 0.03721 | – | |
| Cubic model | 134.06 | −1.5385 | 0.09416 | −0.00166 | |
| No SICH by mSITS | Linear model | 131.99 | −0.21927 | – | – |
| Quadratic model | 134.06 | −0.94195 | 0.03302 | – | |
| Cubic model | 134.57 | −1.2899 | 0.07348 | −0.00118 | |
| No ICH | Linear model | 132.22 | −0.22255 | – | – |
| Quadratic model | 134.27 | −0.93689 | 0.03259 | – | |
| Cubic model | 134.93 | −1.3832 | 0.08448 | −0.00151 |
ICH, intracerebral haemorrhage; mRS, Modified Rankin Scale; mSITS, Modified Safe Implementation of Treatment in Stroke; SICH, symptomatic intracerebral haemorrhage.
Figure 3Fixed effects from the mixed effects models for each favourable outcome by prediction model version. (A) mRS score of 0–2 at 3 months. (B) alive by 3 months. (C) No SICH on follow-up radiological examination. (D) No ICH on follow-up radiological examination. Solid line indicates the linear model; dashed line denotes the quadratic model; dotted line indicates the cubic model. EVT, endovascular thrombectomy; ICH, intracerebral haemorrhage; mRS, Modified Rankin Scale; SBP, systolic blood pressure; SICH, symptomatic intracerebral haemorrhage.
AUC values for the prediction model versions, by hours of SBP measurements testing the models
| Outcome | Model | 24 hours | 18 hours | 12 hours | 6 hours |
| mRS score 0–2 at 3 months | Linear model | 0.830 | 0.833 | 0.835 | 0.820 |
| Quadratic model | 0.837 | 0.835 | 0.836 | 0.823 | |
| Cubic model | 0.837 | 0.835 | 0.836 | 0.823 | |
| Alive at 3 months | Linear model | 0.799 | 0.797 | 0.801 | 0.795 |
| Quadratic model | 0.801 | 0.800 | 0.801 | 0.795 | |
| Cubic model | 0.801 | 0.800 | 0.801 | 0.795 | |
| No SICH by mSITS | Linear model | 0.636 | 0.679 | 0.650 | 0.662 |
| Quadratic model | 0.633 | 0.669 | 0.653 | 0.667 | |
| Cubic model | 0.632 | 0.669 | 0.655 | 0.666 | |
| No ICH | Linear model | 0.604 | 0.608 | 0.600 | 0.594 |
| Quadratic model | 0.603 | 0.610 | 0.605 | 0.596 | |
| Cubic model | 0.628 | 0.637 | 0.628 | 0.612 |
AUC, area under the curve; ICH, intracerebral haemorrhage; mRS, Modified Rankin Scale; mSITS, Modified Safe Implementation of Treatment in Stroke; SICH, symptomatic intracerebral haemorrhage.